XenoPort, Inc. clinical trials

Acquired by Azurity Pharmaceuticals

The registry lists 26 studies whose lead sponsor is XenoPort, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 9, 2021.

Studies

Recruiting first, then most recently updated. Showing 26 of 26. All Azurity Pharmaceuticals studies →

• An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLSStatus unknownNCT02560766Phase 4

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLSStatus unknownNCT02633683Phase 4

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment StudyCompletedNCT01668667Phase 4

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease SubjectsCompletedNCT00914602Phase 1/2

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLSWithdrawnNCT02633657Phase 1

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy VolunteersCompletedNCT01516372Phase 1

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord InjuryCompletedNCT00557973Phase 2

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple SclerosisCompletedNCT01359566Phase 3

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERDCompletedNCT00557401Phase 2

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back SpasmsCompletedNCT00817986Phase 2

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)CompletedNCT00978016Phase 2

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease SubjectsCompletedNCT01171313Phase 2

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• Simulated Driving Study in Restless Legs SyndromeCompletedNCT01332318Phase 2

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)CompletedNCT00619476Phase 2

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)CompletedNCT00643760Phase 2

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.CompletedNCT00311363Phase 3

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome.CompletedNCT00333359Phase 3

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• XP13512 vs. Placebo in Patients With Restless Legs Syndrome.CompletedNCT00365352Phase 3

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• Prevention Study in Adult Patients Suffering From Migraine HeadachesCompletedNCT00742209Phase 2

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs SyndromeCompletedNCT01332305Phase 2

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin TreatmentCompletedNCT00617461Phase 2

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep DisturbanceCompletedNCT00748098Phase 3

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy SubjectsCompletedNCT01411124Phase 1

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• Drug Drug Interaction Study With Gabapentin Enacarbil and MorphineCompletedNCT01476124Phase 1

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• Relative Bioavailability Study for GSK1838262 (Gabapentin Enacarbil)CompletedNCT00833391Phase 1

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group

• XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome.CompletedNCT00298623Phase 3

  Sponsor listed in the registry: XenoPort, Inc. · XenoPort, Inc. — acquired company within the Azurity Pharmaceuticals group